Can peripheral blood eosinophils predict primary non-response to Infliximab therapy in pediatric Crohn’s disease?
Authors:
- 12 April 2026
- journal article
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 50 (5) , 102829
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition, 2025
- Mo1517: LONGITUDINAL MULTI-OMICS ANALYSIS IDENTIFIES EARLY BLOODBASED PREDICTORS OF ANTI-TNF THERAPY RESPONSE IN INFLAMMATORY BOWEL DISEASEGastroenterology, 2022
- Pediatric Inflammatory Bowel Disease in Asia: Epidemiology and natural historyPediatrics & Neonatology, 2020
- 78 Incidence and Phenotype of Inflammatory Bowel Disease From 13 Countries in Asia-Pacific: Results From the Asia-Pacific Crohn's and Colitis Epidemiologic Study 2011-2013Gastroenterology, 2016
- Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseJournal of Crohn's and Colitis, 2014
- High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatmentJournal of Crohn's and Colitis, 2014
- Management of Active Crohn DiseaseJAMA, 2013
- Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experienceJournal of Crohn's and Colitis, 2012
- Anti-TNF therapy: Safety aspects of taking the riskAutoimmunity Reviews, 2011
- Induction and Maintenance Adalimumab Therapy for the Treatment of Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2011